Combination therapy may be more effective against the most common ovarian cancer

3 agosto 2015

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery. Now a team of researchers has discovered that a subset of tumor cells that don’t produce the protein CA125, a biomarker used to test for ovarian cancer, has an enhanced ability to repair their DNA and resist programmed cell death — which allows the cells to evade the drug and live long enough to regrow the original tumor.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/ytXmKpL4ZvU» height=»1″ width=»1″ alt=»»/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/ytXmKpL4ZvU/150803083712.htm

Volver